Short Bowel Syndrome Market Size and Growth Forecast for Businesses 2025–2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Short Bowel Syndrome Market?

The short bowel syndrome market size has seen rapid expansion in recent years. It is anticipated to increase from $2.69 billion in 2024 to $3.08 billion in 2025, achieving a compound annual growth rate (CAGR) of 14.6%. The historical growth of this market can be attributed to several factors including the rising prevalence of gastrointestinal disorders, increasing healthcare expenditure and insurance coverage, enhancements in the post-surgical management of SBS, an uptick in the prevalence of Crohn’s disease and other GI disorders, and improved parenteral nutrition formulations and administration techniques.

The market for short bowel syndrome is projected to experience swift expansion over the coming years. This market is anticipated to reach $5.29 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 14.4%. This projected growth is primarily driven by factors such as the increasing incidence of short bowel syndrome (SBS), wider acceptance of parenteral and enteral nutrition therapies, advancements in clinical research and drug discovery, greater healthcare spending, and improved public awareness leading to earlier diagnosis of SBS. Key trends expected during this period involve enhancements in intestinal rehabilitation treatments, the evolution of small intestine transplantation methods, the utilization of telemedicine for managing SBS, innovations in enteral feeding device technology, and the incorporation of artificial intelligence into SBS treatment strategies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23515&type=smp

Which Industry Drivers Are Expected To Accelerate The Short Bowel Syndrome Market From 2025 To 2029?

The short bowel syndrome market is anticipated to expand due to the rising occurrence of gastrointestinal illnesses. Gastrointestinal diseases encompass various conditions affecting the digestive system, such as those impacting the stomach, intestines, liver, and pancreas, frequently resulting in poor digestion and nutrient uptake. Unhealthy eating patterns, which negatively affect gut health and trigger inflammation, are a major contributor to the increasing incidence of gastrointestinal diseases. These diseases can lead to short bowel syndrome when surgical removal of compromised intestinal parts becomes necessary, thereby diminishing the gut’s ability to absorb nutrients. For example, data from September 2023, provided by the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canadian organization focused on enhancing the lives of patients with Crohn’s disease and ulcerative colitis, indicated that in 2023, over 320,000 people in Canada were affected by inflammatory bowel disease (IBD), showing a prevalence of 825 per 100,000. With an anticipated annual increase in prevalence of 2.44%, projections suggest that by 2035, 1.1% of the population, or 470,000 Canadians, will be living with IBD. Consequently, the rising occurrence of gastrointestinal conditions is a key factor propelling the expansion of the short bowel syndrome market.

What Are The Key Segments In The Short Bowel Syndrome Market?

The short bowel syndromemarket covered in this report is segmented –

1) By Type: Glucagon-Like Peptide (GLP-2); Growth Hormone; Glutamine

2) By Diagnosis: Physical Exam; Blood Tests; Fecal Fat Tests; Imaging Procedures; Other Diagnosis

3) By Treatment: Nutritional Therapy; Medications; Surgery; Transplant

4) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Other Distribution Channels

Subsegments:

1) By Glucagon-Like Peptide (GLP-2): Teduglutide; Other GLP-2 Analogues

2) By Growth Hormone: Somatropin; Other Growth Hormone Therapies

3) By Glutamine: Oral Glutamine; Intravenous Glutamine

Which Ongoing Trends Are Expected To Shape The Short Bowel Syndrome Market Outlook?

Leading companies in the short bowel syndrome market are prioritizing the development of innovative breakthroughs in medical science, such as therapies for intestinal failure, to offer an advanced treatment choice that enhances results for individuals with gastrointestinal conditions. Intestinal failure is a severe condition where the small intestine cannot adequately absorb enough nutrients, fluids, and electrolytes to maintain proper hydration and nutrition. For instance, in May 2024, Ironwood Pharmaceuticals, Inc., a US healthcare enterprise, presented new data from studies assessing apraglutide in adults with short bowel syndrome and intestinal failure (SBS-IF). As a next-generation GLP-2 analog, apraglutide exhibited the potential to improve intestinal absorption and lessen dependence on parenteral support. These findings underscore the drug’s effectiveness, safety, and long-term advantages, reflecting Ironwood’s dedication to developing innovative treatments for gastrointestinal disorders.

Who Are The Core Companies Influencing The Short Bowel Syndrome Market Landscape?

Major companies operating in the short bowel syndrome market are Nestlé SA, Pfizer Inc, Johnson & Johnson, Sanofi SA, Nutrinia, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Zealand Pharma, Baxter International Inc., Alnylam Pharmaceuticals, OPKO Health Inc, Ironwood Pharmaceuticals Inc., Hanmi Pharm Co. Ltd, Ardelyx Inc, Emmaus Life Sciences Inc, Jaguar Health, 9 Meters Biopharma Inc., OxThera Inc. , Adocia SAS, EnteraBio Ltd, GLyPharma Therapeutic Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report

What Are The Key Regional Factors Influencing The Short Bowel Syndrome Market Growth?

North America was the largest region in the short bowel syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Short Bowel Syndrome Market Report:

https://www.thebusinessresearchcompany.com/customise?id=23515&type=smp

Browse Through More Reports Similar to the Global Short Bowel Syndrome Market 2025, By The Business Research Company

Inflammatory Bowel Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Irritable Bowel Syndrome Ibs Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/irritable-bowel-syndrome-ibs-treatment-global-market-report

Cough Hypersensitivity Syndrome Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cough-hypersensitivity-syndrome-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795